Skip to main content

Day: March 11, 2025

ACV Announces Transfer of Listing of Common Stock to the New York Stock Exchange

BUFFALO, N.Y., March 11, 2025 (GLOBE NEWSWIRE) — ACV (Nasdaq: ACVA), a leading digital automotive marketplace and data services partner for dealers and commercial clients, announced today that it will transfer the listing and trading of its common stock to the New York Stock Exchange (“NYSE”) from the Nasdaq Stock Market LLC (“Nasdaq”). ACV’s common stock is expected to begin trading on the NYSE on March 24, 2025, and will continue to be traded under its current ticker symbol “ACVA.” ACV’s common stock is expected to continue to trade on Nasdaq until the close of the market on March 21, 2025. “We are excited to announce the transfer of our company’s stock listing to the NYSE, which represents another step in our journey as a public company,” said Bill Zerella, CFO of ACV. “We believe the NYSE’s market infrastructure and global...

Continue reading

Brera Holdings Hosts Inaugural Investor Weekend at its Italian Serie B Football Club Juve Stabia, ‘The Second Team of Naples,’ Showcasing Sport, Culture, and Strategic Growth

Brera Holdings Executive Chairman Daniel McClory and Juve Stabia President Andrea Langella, with Brera investors, at the Juve Stabia – Cittadella matchBrera Holdings Executive Chairman Daniel McClory and Juve Stabia President Andrea Langella, with Brera investors, at the Juve Stabia – Cittadella matchBrera investors and partners on the famous Gulf of Naples, next to the famous Castel dell’Ovo of NaplesBrera investors and partners on the famous Gulf of Naples, next to the famous Castel dell’Ovo of NaplesA visit to Juve Stabia academy at Cercola Training Center in Naples, with U-13s picturedA visit to Juve Stabia academy at Cercola Training Center in Naples, with U-13s picturedDublin, Ireland and Naples, Italy, March 11, 2025 (GLOBE NEWSWIRE) — Brera Holdings PLC (“Brera” or the “Company”) (Nasdaq:...

Continue reading

Armlogi Holding Corp. Reports 20% Workforce Expansion Since Mid-2023

Measured Hiring Strategy to Support Operational Excellence and Service Capabilities WALNUT, CA, March 11, 2025 (GLOBE NEWSWIRE) — Armlogi Holding Corp. (“Armlogi” or the “Company”) (Nasdaq: BTOC), a U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions related to warehouse management and order fulfillment, today announced workforce expansion, with employee headcount increasing by 20% over the past 20 months. Armlogi has adopted a disciplined approach to scaling its operations, as it endeavors to maintain service quality.  Since July 2023, Armlogi grew from 173 employees to 208 employees as of March 2025. This measured expansion aligns with increasing client demand and the Company’s enhanced service offerings. “We believe that our workforce development strategy...

Continue reading

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights:CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025. New data published in JACC: Heart Failure showed Aquadex ultrafiltration reduced heart failure events by 60% compared to IV diuretics. Full year operating cost reduction of $5.9 million, or 26%, compared to the prior year. Revenue of $2.3 million, a 9% decrease compared to the prior year quarter. Consumables utilization growth of 21% compared to the prior year quarter. Critical Care customer category revenue...

Continue reading

PharmaTher Receives US FDA Approval Goal Date for Ketamine

The Assigned FDA Approval Goal Date is June 4, 2025 TORONTO, March 11, 2025 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company hyper-focused on the commercialization of Ketamine, is pleased to announce today that the Company has received an Amendment Acknowledgement Letter (“AAL”) from the U.S. Food and Drug Administration (“FDA”) for its New Drug Application for Ketamine. In the AAL, the FDA determined this is a minor amendment, meets the criteria for priority review, and assigned an approval goal date of June 4, 2025. Fabio Chianelli, Chairman and CEO of PharmaTher, commented: “I am very pleased with the new FDA approval goal date of June 4, 2025 for our Ketamine drug. We are focused on solving the shortage issue of Ketamine and becoming...

Continue reading

Abacus Life Announces Rebrand to Abacus Global Management, Unveils Expanded Business Lines

Strategic name change reflects company’s evolution and global market presence ORLANDO, Fla., March 11, 2025 (GLOBE NEWSWIRE) — Abacus Life (NASDAQ: ABL), a leader in the alternative asset management space, today announced it has rebranded to Abacus Global Management (abacusgm.com), effective immediately. The new name better reflects the company’s expanded global presence and comprehensive suite of financial services spanning life solutions, asset management, wealth management, and technology solutions. The company’s focus on innovative technology represents a core and growing part of its business strategy going forward. “Our evolution to Abacus Global Management represents a significant milestone in our company’s journey, to revolutionize financial services though expert asset management leveraging advanced technology and to deliver...

Continue reading

AVID Partners with Super League to Launch Educational Experience on Roblox Focused on Executive Function and Durable Skills

Funded by a grant from the Roblox Community Fund, AVID’s Creator Planet integrates with key educational standards and includes free classroom resources for teachers and students SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) — Today, AVID (Advancement Via Individual Determination), a leader in closing the opportunity gap for students, and Super League (Nasdaq: SLE), a leader in redefining the gaming industry as a media channel, announce the launch of AVID Creator Planet, an educational adventure on Roblox designed for students ages 13+ to learn valuable executive function and durable skills in and out of the classroom. Funded by a grant from the Roblox Community Fund, AVID Creator Planet focuses on practicing durable skills such as problem-solving, critical thinking, collaboration, and communication. Each phase – from planning and...

Continue reading

iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025

NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, March 19, 2025. Earnings call details are as follows: Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 174549Webcast: https://www.webcaster4.com/Webcast/Page/2879/52064 About iCAD, Inc. iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua,...

Continue reading

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) —  Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity. The assay leverages...

Continue reading

Enphase Energy Launches Next-Generation IQ EV Charger across Europe

FREMONT, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced production shipments of its newest electric vehicle (EV) charger, the IQ® EV Charger 2, in 14 European markets. The IQ EV Charger 2 is a smart charger designed to work seamlessly with Enphase solar and battery systems or as a powerful standalone charger. With advanced energy management features, the charger empowers homeowners to maximize solar self-consumption, lower energy costs, and enjoy a smart, efficient EV charging experience. The IQ EV Charger 2 is now available in Norway, Germany, the United Kingdom (UK), France, the Netherlands, Sweden, Denmark, Switzerland, Austria, Belgium, Luxembourg, Italy,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.